SUSAN ENG-MA: Open Payments
NPI 1477687754 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,346 in 50 payments from 18 companies in 2025. Trend: 2023 $4,177 · 2024 $3,523 · 2025 $3,346
Food & beverage: $3,279Education: $67
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 4 | $431 |
| AstraZeneca Pharmaceuticals LP | 3 | $369 |
| GlaxoSmithKline, LLC. | 4 | $312 |
| AKEBIA THERAPEUTICS INC | 3 | $287 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $273 |
| Lilly USA, LLC | 2 | $250 |
| Calliditas Therapeutics US Inc. | 5 | $227 |
| PFIZER INC. | 2 | $215 |
| Otsuka America Pharmaceutical, Inc. | 4 | $200 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $150 |
Products named: BENLYSTA, TAVNEOS, Vafseo, JARDIANCE, LOKELMA, TARPEYO, PREVNAR 20, REZDIFFRA.
Industry payments across NY — which companies pay providers there.
